Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816971 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 5
- Study locations
NCT01816971 is a Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 76 participants, above the 69-participant average among 4 other Stage III Multiple Myeloma trials with a reported enrollment target (10% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT01816971, a Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from diving. Giving carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant may kill more cancer cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG carfilzomib
- PROCEDURE autologous hematopoietic stem cell transplantation
Study Locations (5)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Massachusetts
- Dana Farber - Boston
Missouri
- Washington University in St Louis - St Louis
Tennessee
- Sarah Cannon Cancer Center - Nashville
Ontario
- Princess Margaret - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-01 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816971
The ClinicalTrials.gov registry entry for NCT01816971 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 69-participant average among 4 other Stage III Multiple Myeloma trials with a reported enrollment target (10% higher). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage III Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01816971 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT01816971 about?
NCT01816971 is a clinical study titled "Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological...
What is the current status of trial NCT01816971?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2013-01. Estimated completion is 2026-12-01.
What conditions does trial NCT01816971 study?
This clinical trial studies the following conditions: Stage III Multiple Myeloma, Stage II Multiple Myeloma, Stage I Multiple Myeloma.
What interventions are being tested in trial NCT01816971?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), lenalidomide (DRUG), carfilzomib (DRUG), autologous hematopoietic stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT01816971?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01816971 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, Missouri, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
COMPLETED · Phase 2
-
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
COMPLETED · Phase 3
-
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.